BMY vs GTBP · P/E 17, rev $24.46B vs $17.4M cap
Bristol-Myers Squibb Company (BMY) versus GT Biopharma Inc (GTBP) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
GT Biopharma Inc (GTBP) is a biotechnology company listed on NASDAQ.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
GTBP does not have a complete income-statement cache yet.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. GTBP currently screens at market cap $17.4M.
Not investment advice. Open the BMY and GTBP stock pages for the full models.
Not investment advice.